Please use this identifier to cite or link to this item:
Title: In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody.
Austin Authors: Pietersz, Geoffrey A;Toohey, B;McKenzie, Ian F C
Affiliation: The Austin Research Institute, Austin Hospital, Heidelberg Victoria, Australia
Issue Date: 16-May-1998
Publication information: Journal of Drug Targeting; 5(2): 109-20
Abstract: Human tumor necrosis-alpha (hTNF-alpha) was chemically conjugated to the murine anti-Ly-2.1 T cell antibody using heterobifunctional crosslinking agents SAMSA and SPDP. SDS-PAGE analysis of the affinity purified conjugate consisted mainly of 1:1 and 1:2 (Ly-2.1:TNF) complexes. Conjugated hTNF retained 50% of its cytotoxic activity by the L929 cytolytic assay, with an IC50 = 0.12 ng/ml. hTNF-Ly-2.1 was also cytotoxic to E3 cells (Ly-2.1+ve) with an IC50 = 1.7 microg/ml - 3 times more cytotoxic to these cells than non-conjugated hTNF in vitro. However in vivo hTNF-Ly-2.1 conjugates were more toxic to mice than hTNF. In vivo blood clearance studies in E3 tumor bearing CBF1 mice demonstrated that the half life of the conjugate was 2 hr, compared to 20 min for hTNF. In biodistribution studies, tumor accumulation of 3% was seen for hTNF-Ly-2.1 while for unconjugated hTNF no activity in tumor was detected 24hr post injection. A single dose of hTNF-Ly-2.1 increased the accumulation of 125I-anti-Ly-2.1 by 3 fold compared to controls. However, the antitumor effect of hTNF-Ly-2.1 on E3 cells in vivo was marginal with some tumor growth retardation at day 1-3. The results of these in vitro and in vivo studies on chemically conjugated h-TNF-MoAb will be helpful in the design of novel recombinant fusion proteins for targeting the biologic activity of TNF to tumours.
Gov't Doc #: 9588867
DOI: 10.3109/10611869808995864
Journal: Journal of drug targeting
Type: Journal Article
Subjects: Animals
Antibodies, Monoclonal.chemistry
Cell Line
Drug Evaluation
Immunoconjugates.administration & dosage.isolation & purification.pharmacokinetics
Recombinant Proteins.administration & dosage.pharmacokinetics
Thymus Neoplasms.metabolism
Tissue Distribution
Tumor Necrosis Factor-alpha.chemistry.pharmacokinetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.